cardiomyopathy

Immunosuppressive drugs as a tool to explore immunopathology in experimental Chagas disease

Immunopathology of cardiomyopathy in the experimental Chagas disease

Studies of membrane fluidity and heart contractile force in Trypanosoma cruzi infected mice

Clinical forms of Trypanosoma cruzi infected individuals in the chronic phase of Chagas disease in Puebla, Mexico

Current status and perspectives of cell therapy in Chagas disease

Chronic Trypanosoma cruzi-elicited cardiomyopathy: from the discovery to the proposal of rational therapeutic interventions targeting cell adhesion molecules and chemokine receptors - how to make a dream come true

Back to the future in Chagas disease: from animal models to patient cohort studies, progress in immunopathogenesis research

The benefits of using selenium in the treatment of Chagas disease: prevention of right ventricle chamber dilatation and reversion of Trypanosoma cruzi-induced acute and chronic cardiomyopathy in mice

Severity of chronic experimental Chagas' heart disease
parallels tumour necrosis factor and nitric oxide levels in the serum: models of
mild and severe disease

Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy

Single nucleotide polymorphisms of cytokine-related genes and association with clinical outcome in a Chagas disease case-control study from Brazil

Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland

Antiparasitic and anti-inflammatory activities of ß-lapachone-derived naphthoimidazoles in experimental acute Trypanosoma cruzi infection

Inscrever-se em cardiomyopathy